Physician profile
Donna M Smith
NPI 1164485272
$13,429.95
in general payments reported to CMS, 2019-2025
43 companies · $2,548 in 2025
The $2,548 reported for 2025 was more than what 96% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,124 · 2022: $628 · 2023: $3,673 · 2024: $4,456 · 2025: $2,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,177 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,300 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,177.28 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,300.00 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,795.31 | 2021-2025 | |
| Lundbeck LLC | $1,010.96 | 2021-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $758.25 | 2021-2025 | Amyvid, Kisunla, Emgality |
| Novartis Pharmaceuticals Corporation | $507.08 | 2022-2025 | |
| Pfizer INC. | $497.42 | 2023-2025 | |
| Eisai INC. | $398.91 | 2023-2025 | |
| Ucb, INC. | $294.32 | 2021-2024 | Rystiggo, Nayzilam, Zilbrysq |
| Avadel Cns Pharmaceuticals, LLC | $287.70 | 2024-2025 | Lumryz |
| Biohaven Pharmaceuticals, INC. | $283.12 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $270.24 | 2021-2025 | Ajovy, Austedo Xr |
| Argenx US, INC. | $220.28 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Celgene Corporation | $216.98 | 2023-2025 | Zeposia |
| Amgen INC. | $214.27 | 2021-2024 | Aimovig |
| Biogen, INC. | $166.90 | 2021-2025 | Leqembi, Vumerity |
| Genentech USA, INC. | $163.08 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.